
Applying Recent Trial Data to mHSPC Clinical Decision-Making
Metastatic hormone-sensitive prostate cancer (mHSPC) has a growing number of effective treatment options that combine androgen deprivation therapy (ADT) with novel hormonal agents. During a live Community Case Forum in Frisco, Texas, Tian Zhang, MD, MHS, …